NRx Pharmaceuticals Statistics
Total Valuation
NRXP has a market cap or net worth of $37.77 million. The enterprise value is $43.23 million.
| Market Cap | 37.77M |
| Enterprise Value | 43.23M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, after market close.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NRXP has 10.70 million shares outstanding. The number of shares has increased by 33.17% in one year.
| Shares Outstanding | 10.70M |
| Shares Change (YoY) | +33.17% |
| Shares Change (QoQ) | +9.69% |
| Owned by Insiders (%) | 26.87% |
| Owned by Institutions (%) | 3.61% |
| Float | 6.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18
| Current Ratio | 0.18 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -72.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -233.00% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$12.82M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.50% in the last 52 weeks. The beta is 1.15, so NRXP's price volatility has been higher than the market average.
| Beta (1Y) | 1.15 |
| 52-Week Price Change | -45.50% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 3.70 |
| Relative Strength Index (RSI) | 51.86 |
| Average Volume (30 Days) | 444,297 |
Short Selling Information
The latest short interest is 486,173, so 4.54% of the outstanding shares have been sold short.
| Short Interest | 486,173 |
| Short Previous Month | 510,829 |
| Short % of Shares Out | 4.54% |
| Short % of Float | 7.54% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.40M |
| Pretax Income | -25.64M |
| Net Income | -25.65M |
| EBITDA | -25.28M |
| EBIT | -25.29M |
| Earnings Per Share (EPS) | -$3.14 |
Balance Sheet
The company has $1.32 million in cash and $6.78 million in debt, giving a net cash position of -$5.46 million or -$0.51 per share.
| Cash & Cash Equivalents | 1.32M |
| Total Debt | 6.78M |
| Net Cash | -5.46M |
| Net Cash Per Share | -$0.51 |
| Equity / Book Value | -15.07M |
| Book Value Per Share | -1.41 |
| Working Capital | -15.51M |
Cash Flow
In the last 12 months, operating cash flow was -$19.24 million and capital expenditures $1,000, giving a free cash flow of -$19.24 million.
| Operating Cash Flow | -19.24M |
| Capital Expenditures | 1,000 |
| Free Cash Flow | -19.24M |
| FCF Per Share | -$2.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.17% |
| Shareholder Yield | -33.17% |
| Earnings Yield | -67.90% |
| FCF Yield | -50.93% |
Analyst Forecast
The average price target for NRXP is $20.00, which is 468.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 468.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 2, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |